NCT04333914

Who might be able to join this trial:

• Women aged 18 or older, or men aged 60 or older at the time of joining the trial
• You have a confirmed diagnosis of an advanced or spreading blood cancer or solid tumour (any type, anywhere in the body), confirmed by laboratory testing
• You have a confirmed COVID-19 diagnosis from a certified laboratory, and do not need to be moved to an intensive care unit; for the milder group (Cohort 1), no more than 7 days should have passed since your first symptoms; for the more severe group (Cohort 2), no more than 10 days
• Cohort 2 only: You have pneumonia confirmed by a chest scan, and your blood oxygen levels are at or below a certain level while breathing normal air (confirm with trial site)
• A medical team has agreed that you are not suitable for transfer to an intensive care unit, either because of your overall health condition or because no beds are available
• Your doctors expect you to live for more than 3 months
• Your blood counts, liver, and kidney are working at an acceptable level based on recent blood tests (confirm exact values with trial site)
• You are willing and able to follow all the study requirements
• You have read and signed a consent form showing you understand and agree to take part in the trial
• Women who could become pregnant must have a negative pregnancy blood test within 72 hours before starting treatment
• Women who could become pregnant and male participants must agree to use highly effective contraception during the trial and for up to 6 months after finishing treatment
• You have medical insurance coverage

Who may not be able to join:

• Cohort 1 only: You are currently receiving a specific type of treatment called an anti-NKG2A therapy (confirm with trial site)
• Cohort 2 only: You are currently receiving a specific type of treatment called an anti-C5aR therapy (confirm with trial site)
• You have a known allergy or serious reaction to the study drugs (monalizumab for Cohort 1, or avdoralimab for Cohort 2), or a severe allergic reaction to any similar antibody-based medicine
• Cohort 1 only: You are known to be intolerant or allergic to chloroquine or related medicines (such as hydroxychloroquine or quinine); or you have taken these medicines and have not stopped them at least 72 hours before joining
• You have an active autoimmune disease (where the immune system attacks the body) that has needed treatment in the past 3 months, or a serious history of such a condition, or you need high doses of steroid or immune-suppressing medicines (some exceptions apply — confirm with trial site)
• You need major surgery or live vaccines (such as measles, mumps, rubella, or chickenpox vaccines) during the study treatment period
• You have significant heart problems, such as a recent heart attack within the past 3 months, serious irregular heartbeat, unstable chest pain, or poor heart pumping function (confirm with trial site)
• You have active hepatitis B, active hepatitis C, or a known HIV infection
• You have previously had a bone marrow transplant from a donor or a solid organ transplant at any time in the past
• Your doctor believes your health condition, other treatments, or test results could interfere with the trial or that participation would not be in your best interest
• You have a known psychiatric condition or substance use problem that would make it difficult to follow the trial requirements
• You are pregnant, breastfeeding, or planning to become pregnant during the trial or within 6 months of the last dose of the study medicine

Important: Always verify eligibility with the trial site directly before applying.